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http://dx.doi.org/10.1016/j.jacl.2014.11BACKGROUND: Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid
ethyl ester approved at a dose of 4 g/day as an adjunct to diet to reduce triglyceride (TG) levels in adult
patients with severe hypertriglyceridemia (TG $ 500 mg/dL).
OBJECTIVE: In this prespecified exploratory analysis from the ANCHOR study of patients at high
cardiovascular risk with TG $ 200 and ,500 mg/dL despite statin control of low-density lipoprotein
cholesterol, we assessed the effects of IPE on lipoprotein particle concentration and size and examined
correlations of atherogenic particles with apolipoprotein B (ApoB).
METHODS: Nuclear magnetic resonance spectroscopy was used to measure lipoprotein particle con-
centration and size.
RESULTS: Compared with placebo (n 5 211), IPE 4 g/day (n 5 216) significantly reduced concen-
trations of: total (12.2%, P 5 .0002), large (46.4%, P , .0001), and medium (12.1%, P 5 .0068)
very-low-density lipoprotein (VLDL) particles; total (7.7%, P 5 .0017) and small (13.5%,
P , .0001) LDL particles; and total (7.4%, P , .0001) and large (31.0%, P , .0001) high-density
lipoprotein particles. Atherogenic lipoprotein particles (total VLDL and total LDL) correlated with
ApoB at baseline (R2 5 0.57) and week 12 (R2 5 0.65) as did total LDL particle concentration at base-
line (R2 5 0.53) and week 12 (R2 5 0.59). Compared with placebo, IPE 4 g/day significantly reduced
VLDL (7.7%, P , .0001) and high-density lipoprotein (1.2%, P 5 .0014) particle sizes with a modest
but significant increase in LDL particle size (0.5%, P 5 .0031).red by Amarin Pharma Inc., Bed-
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378 Journal of Clinical Lipidology, Vol 9, No 3, June 2015CONCLUSIONS: Compared with placebo, treatment with IPE 4 g/day for 12 weeks reduced key
atherogenic lipoprotein particle concentrations. At both baseline and end of study, atherogenic lipopro-
tein concentrations correlated with ApoB.
 2015 National Lipid Association. This is an open access article under the CCBY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Icosapent ethyl (IPE; Vascepa; Amarin Pharma Inc.,
Bedminster, NJ) is a high-purity prescription form of
eicosapentaenoic acid (EPA) ethyl ester approved by the
US Food and Drug Administration as an adjunct to diet to
reduce triglyceride (TG) levels in adult patients with severe
($500 mg/dL) hypertriglyceridemia.1 The Multi-Center,
Placebo-Controlled, Randomized, Double-Blind, 12-week
study with an open-label Extension (MARINE)
(N 5 229) demonstrated that, compared with placebo,
IPE 4 g/day significantly reduced levels of TG (33.1%,
P , .0001), total cholesterol (TC; 16.3%, P , .0001),
non–high-density lipoprotein cholesterol (non-HDL-C;
17.7%, P , .0001), and apolipoprotein B (ApoB; 8.5%,
P 5 .0019) in patients with very high TG levels ($500
and #2000 mg/dL) without significantly increasing low-
density lipoprotein cholesterol (LDL-C).2
The ANCHOR study evaluated IPE in statin-treated
patients at high risk for cardiovascular disease with
persistently high TG ($200 and ,500 mg/dL) and well-
controlled LDL-C ($40 and #115 mg/dL).3 Compared
with placebo, IPE 4 g/day significantly (all P , .0001)
reduced levels of TG (21.5%), TC (12.0%), non-HDL-C
(13.6%), and ApoB (9.3%); LDL-C was also significantly
reduced by 6.2% (P 5 .0067).3
Although the non-HDL-C–lowering effects of lipid-
lowering agents are central in clinical practice for the
management of cardiovascular disease and risk, lipoprotein
particle parameters and ApoB may also be clinically
relevant and useful.4,5 Lipoprotein particle concentration,
LDL particle size, and ApoB levels may influence athero-
genicity and coronary heart disease risk.6–9 Indeed, LDL
particle concentrations and/or ApoB have been included
in recent treatment recommendations and consensus state-
ments regarding lipid management.9–12
The objective of this prespecified exploratory analysis
from the ANCHOR study was to assess the effects of IPE
on lipoprotein particle concentration and size and to assess
the correlation of LDL and total atherogenic particle
concentrations with ApoB in statin-treated patients.Methods
ANCHOR was a phase 3, 12-week, multicenter, double-
blind, randomized, placebo-controlled study of IPE inpatients receiving atorvastatin, rosuvastatin, or simvastatin
with or without ezetimibe and at high cardiovascular risk
with TG levels $200 and ,500 mg/dL and LDL-C levels
$40 and #115 mg/dL.3 Briefly, eligible patients aged
.18 years entered a 4- to 6-week diet, lifestyle, and medi-
cation stabilization lead-in period with washout of pro-
hibited non-statin lipid-altering medications (including
fibrates, niacins, and omega-3 fatty acids). This was fol-
lowed by a 2- to 3-week lipid-qualifying period after which
patients entered the 12-week treatment period with IPE
4 g/day, IPE 2 g/day, or matched placebo.3 This brief report
focuses on the Food and Drug Administration–approved
dose of 4 g/day.
Lipoprotein particle concentration and size were
measured by nuclear magnetic resonance spectroscopy at
LipoScience, Inc. (Raleigh, NC), as previously described.13
Statistical analyses were performed using SAS 9.2 soft-
ware. The data set included values from the intent-to-treat
(ITT) population, defined as all randomized patients who
had a baseline TG primary efficacy end point measurement,
received $1 dose of study drug, and had $1 postrandom-
ization efficacy measurement. Patients with missing
baseline or week 12 measurements were excluded. Lipo-
protein particle end points were prespecified and explor-
atory with statistical significance predefined as P # .05;
no adjustments were made for multiplicity. Medians and in-
terquartile ranges were calculated for each treatment group
at baseline, week 12, and for percent change from baseline
at week 12. Between-treatment differences in percent
change from baseline for each lipoprotein particle variable
were examined using the Wilcoxon rank-sum test with
Hodges-Lehmann medians presented. Lipid values and
ApoB were assessed as previously described.3Results
Baseline characteristics were comparable across treat-
ment groups in the ANCHOR study; most patients were
white, overweight men younger than age 65 years with
diabetes mellitus and were receiving medium- or high-
efficacy statin regimens. In this prespecified exploratory
analysis of the ANCHOR study, 216 patients in the IPE
4 g/day group and 211 in the placebo group had evaluable
lipoprotein particle samples, which represented 96% and
93% of the 4 g/day and placebo groups, respectively. In this
subset of patients with lipoprotein data, baseline TG, LDL-
Table 1 Median change in selected lipid end points from baseline to week 12 (patients with lipoprotein analysis)
Lipid end
point (mg/dL)
IPE 4 g/day (n 5 216) Placebo (n 5 211)
Median change
from baseline
Baseline
End of
treatment
Change from
baseline, % Baseline
End of
treatment
Change from
baseline, %
IPE 4 g/day vs
placebo, %, P
TG 264.8 (90.3) 219.3 (91.3) 217.5 (30.4) 258.0 (80.5) 267.5 (141.0) 4.8 (43.6) 221.1
,.0001
LDL-C* 82.0 (24.0) 83.0 (31.0) 2.1 (27.0) 84.0 (27.0) 88.0 (31.0) 7.7 (31.2) 25.2
.0225
Non-HDL-C 128.0 (32.5) 122.0 (37.0) 25.1 (21.4) 128.0 (34.0) 136.0 (42.0) 9.8 (27.2) 213.5
,.0001
HDL-C 38.0 (12.0) 36.5 (13.0) 22.2 (18.5) 39.0 (12.0) 40.0 (14.0) 5.2 (22.0) 25.0
.0005
ApoB 92.5 (23.5) 90.0 (25.5) 22.2 (16.5) 92.0 (25.0) 98.0 (25.0) 7.0 (23.0) 28.8
,.0001
ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; IPE, icosapent ethyl; LDL-C, low-density lipoprotein cholesterol; TG,
triglycerides.
Data are presented as median (interquartile range) for end point values. Median percent changes vs placebo are Hodges-Lehmann medians.
*n 5 210 for placebo.
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between treatment groups and were consistent with those
reported for the ITT population of the ANCHOR study
(Table 1).3 Likewise, similar statistically significant reduc-
tions from baseline to week 12 in TG, LDL-C, non-HDL-C,
HDL-C, and ApoB were observed with IPE 4 g/day
compared with placebo in this analysis as in the ITT popu-
lation from the ANCHOR study (Table 1).3
After 12 weeks of treatment, IPE 4 g/day significantly
reduced concentrations of: total, large, and medium very-
low-density lipoprotein (VLDL) particles; total and small
LDL particles; and total and large HDL particles; and
significantly increased the concentration of large LDL
particles compared with placebo (Table 2). With regard to
particle size, IPE 4 g/day significantly reduced VLDL
and HDL and slightly increased LDL particle size
compared with placebo (Table 2).
At baseline and week 12, concentrations of atherogenic
lipoproteins consisting of all VLDL and LDL particles
correlated with ApoB concentration, as did total LDL
particle concentrations (Fig. 1; all P , .0001).Discussion
This prespecified exploratory analysis of the ANCHOR
study found that, compared with placebo, treatment with
IPE 4 g/day reduced lipoprotein particle concentration in
patients with TG $ 200 and ,500 mg/dL and LDL-C $40
and #115 mg/dL. The levels of LDL-C recorded at
baseline would not generally be considered elevated and
therefore were discordant with the increased concentrations
of other atherogenic lipoproteins. This would be expected
in a high-risk statin-treated patient population with persis-
tently elevated TG levels and, presumably, with increased
concentrations of TG-rich lipoproteins.14 Median baselineLDL-C was 82 and 84 mg/dL in the IPE 4 g/day and pla-
cebo groups, respectively, and was thus well below the
Adult Treatment Panel III target (relevant update at the
time of the ANCHOR study) of ,100 mg/dL.15 Median
baseline non-HDL-C was 128 mg/dL for both the IPE
4 g/day and placebo groups, just below the Adult Treatment
Panel III target of 130 mg/dL.15 However, at baseline, me-
dian ApoB was 93 and 92 mg/dL for the IPE 4 g/day and
placebo groups, respectively, and median total LDL particle
concentration was 1131 and 1152 nmol/L for the IPE
4 g/day and placebo groups, respectively. Although
LDL-C was well below 100 mg/dL and less than the 15th
percentile of the population,16 LDL particle and ApoB con-
centrations remained at about the 40th percentile of the
population17 and higher than suggested target levels,9,18
signifying an atherogenic lipid profile despite low LDL-C
levels. The reductions in total VLDL particle concentration
and size with IPE were consistent with its TG-lowering ef-
fects. After treatment with IPE 4 g/day, the magnitude of
the reduction compared with placebo in total LDL particle
concentration (7.7%, P5 .0017) was consistent with the re-
ductions in ApoB (8.8%, P , .0001) and LDL-C (5.2%,
P 5 .0225) in this patient population. Although IPE 4 g/
day significantly increased LDL particle size, this was a
modest change (0.5%, P 5 .0031). Smaller LDL particles
may potentially be more atherogenic than larger LDL par-
ticles,19–21 but the clinical significance of the increase in
LDL particle size observed here is unclear. Because each
VLDL and LDL particle contains a single ApoB molecule,4
it was expected and confirmed that the concentrations of
atherogenic (VLDL and LDL) particles as well as LDL par-
ticle concentrations correlated with ApoB levels at baseline
and 12 weeks.
Similar exploratory analyses from the MARINE study in
patients with TG$ 500 and#2000 mg/dL showed that IPE
4 g/day significantly reduced the size of VLDL particles
Table 2 Median change from baseline to study end in lipoprotein particle concentration and size
IPE 4 g/day (n 5 216) Placebo (n 5 211)
Median change
from baseline
Baseline
End of
treatment
Change from
baseline, % Baseline
End of
treatment
Change from
baseline, %
IPE 4 g/day vs
placebo, %, P
Lipoprotein particle concentration
Total VLDL, nmol/L 116.7 (66.6) 110.0 (78.0) 22.5 (41.8) 111.2 (50.6) 122.0 (60.0) 7.9 (40.1) 212.2
.0002
Large VLDL, nmol/L 12.9 (10.7) 7.7 (7.6) 241.9 (57.2) 12.9 (9.7) 14.1 (13.2) 6.0 (101.1) 246.4
,.0001
Medium VLDL, nmol/L 54.8 (37.2) 49.7 (41.8) 26.9 (59.3) 53.3 (29.9) 58.8 (36.1) 9.2 (56.3) 212.1
.0068
Small VLDL, nmol/L 43.9 (36.8) 46.8 (39.9) 8.3 (81.8) 41.4 (32.8) 45.3 (37.4) 8.5 (70.0) 2.8
.6321
Total LDL, nmol/L 1131 (369.5) 1191 (512.0) 3.8 (31.8) 1152 (353.0) 1287 (456.0) 11.9 (31.6) 27.7
.0017
IDL, nmol/L 51.5 (81.5) 63.0 (94.0) 23.7 (173.7) 55.0 (88.0) 55.0 (102.0) 0.0 (194.8) 10.0
.3051
Large LDL, nmol/L 113.5 (198.5) 172.5 (226.0) 55.2 (241.0) 113.0 (215.0) 166.0 (271.0) 30.6 (200.4) 34.2
.0076
Small LDL, nmol/L 894.0 (266.5) 902.5 (387.5) 21.1 (36.1) 902.0 (323.0) 978.0 (387.0) 11.0 (39.0) 213.5
,.0001
Total HDL, mmol/L 34.3 (8.9) 32.6 (8.2) 24.0 (16.4) 34.8 (10.1) 35.5 (9.3) 4.7 (16.2) 27.4
,.0001
Large HDL, mmol/L 2.5 (1.8) 1.9 (2.0) 221.6 (58.1) 2.8 (2.0) 2.9 (2.3) 9.1 (50.4) 231.0
,.0001
Medium HDL, mmol/L 6.7 (6.0) 6.9 (4.8) 4.2 (69.4) 7.8 (5.6) 8.3 (7.3) 8.6 (81.8) 26.5
0.2245
Small HDL, mmol/L 24.2 (6.4) 23.1 (6.7) 23.9 (21.9) 23.0 (8.1) 24.0 (7.4) 1.6 (25.4) 22.8
.1267
Lipoprotein particle size
VLDL, nm 56.3 (8.3) 51.2 (8.4) 28.1 (13.7) 56.5 (10.0) 55.9 (11.3) 20.6 (14.3) 27.7
,.0001
LDL,* nm 19.8 (0.5) 20.0 (0.6) 0.5 (2.5) 19.8 (0.6) 19.9 (0.5) 0.0 (2.5) 0.5
.0031
HDL, nm 8.7 (0.3) 8.6 (0.2) 21.1 (3.5) 8.7 (0.3) 8.7 (0.4) 0.0 (3.5) 21.2
.0014
HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; IPE, icosapent ethyl; LDL, low-density lipoprotein; VLDL, very-low-density
lipoprotein.
Data are presented as median (interquartile range) for end point values. Median percent changes vs placebo are Hodges-Lehmann medians.
Diameters are as follows: large VLDL (.60 nm); medium VLDL (42-60 nm); small VLDL (29-42 nm); IDL (23-29 nm); large LDL (20.5-23.0 nm); small
LDL (18.0-20.5 nm); large HDL (9.4-14.0 nm); medium HDL (8.2-9.4 nm); and small HDL (7.3-8.2 nm).
*n 5 215 for IPE 4 g/day.
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(27.9%, P 5 .0211), total LDL (16.3%, P 5 .0006), small
LDL (25.6%, P , .0001), and total HDL particles (7.4%,
P 5 .0063) compared with placebo.13 As in the present
study, the concentration of atherogenic particles correlated
with ApoB at week 12 (R2 5 0.623, P , .0001).13 Results
presented here for the ANCHOR study, together with data
from the MARINE study, demonstrate that treatment with
IPE 4 g/day decreases key atherogenic lipoprotein particle
concentrations as well as ApoB. This may be of potential
clinical benefit because atherogenic lipoprotein particle
concentration and ApoB play important roles in atheroge-
nicity and may be potentially useful in the managementof hypertriglyceridemic patients at increased coronary heart
disease risk. Other exploratory analyses of the MARINE
and ANCHOR studies demonstrated that IPE 4 g/day
decreased Apo C-III22 as well as other key inflammatory
markers associated with cardiovascular disease and athero-
sclerosis including oxidized LDL, lipoprotein-associated
phospholipase A2, and high-sensitivity C-reactive protein
compared with placebo.23
Recent outcome studies have called into question the
benefit of raising HDL-C, and the HDL therapeutic focus
has been shifting to whether there are benefits to altering
HDL function that are not accurately reflected by HDL-C
levels or particle concentration.24–26 In a comprehensive
A B
C D
Figure 1 Correlations at baseline and week 12. Atherogenic particle concentration correlated with apolipoprotein B (ApoB) at (A) base-
line (R2 5 0.57) and (B) week 12 (R2 5 0.65). Total low-density lipoprotein (LDL) particle concentration correlated with ApoB at (C)
baseline (R2 5 0.53) and (D) week 12 (R2 5 0.59). For all correlations, P , .0001 and n 5 427. Bands show 95% confidence limits
of the mean. Atherogenic particle concentration consisted of all very-low-density lipoprotein and LDL particles. IPE, icosapent ethyl.
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on HDL, it was determined that further investigation was
needed regarding the predictive utility of HDL subclass
concentrations and the functional properties of individual
HDL particle sizes and subfractions in the context of dysli-
pidemia.27 Therefore, the implications and clinical rele-
vance of the small but significant change in HDL particle
size observed in this analysis are unknown. Similarly, the
recent American Heart Association and American College
of Cardiology guidelines on cholesterol treatment defer
guidance as to whether on-treatment markers such as
LDL particles are useful for guiding treatment decisions,
and identified these as critical questions, among many
others that future guidelines could examine.28 However,
the National Lipid Association recommendations for
patient-centered management of dyslipidemia do provide
guidance with regard to LDL particles, noting the clinical
utility of measuring LDL particle concentration as an alter-
native to ApoB measurement and in cases where non-HDL-
C and LDL-C goals have been met.29 The statistically
significant reduction in LDL particle concentrationobserved with IPE 4 g/day in this analysis would coincide
with such recommendations.
The mechanisms by which IPE alters lipid and
lipoprotein markers have not been fully elucidated. Studies
suggest that EPA and docosahexaenoic acid (DHA) reduce
hepatic VLDL production and secretion, and increase
clearance of TG-rich lipoproteins.30 Mechanisms relating
to these effects appear to include increased hepatic and
skeletal b-oxidation, reduced ApoB100 secretion,
increased lipoprotein lipase activity, and reduced free
fatty acid release from adipose tissue.30 These results
extend to the postprandial state, where reductions in TG
and ApoB48 have been observed, likely owing in part to
a decrease in ApoB48 secretion, an increase in chylomi-
cron susceptibility to lipoprotein lipase, and decreased
clearance competition from VLDL particles.31–34 From
the limited clinical studies that elucidate EPA effects
from those of DHA, DHA appears to increase LDL-C
levels, whereas EPA does not.35,36 This could be in part
because EPA appears to be more potent than DHA at in-
hibiting diacylglycerol acyl transferase37,38 and at
382 Journal of Clinical Lipidology, Vol 9, No 3, June 2015stimulating lipoprotein lipase and b-oxidation (both, at
least in part, via peroxisome proliferator–activated recep-
tor-a activation),38–40 thereby having potentially greater
effects on TG synthesis and clearance. In addition, animal
models suggest a down-regulation of the LDL receptor
with DHA treatment, which is not observed with EPA
treatment.41 Hence, it could be speculated that the
observed reductions in LDL particle number with IPE
treatment compared with placebo are due, at least in
part, to reductions in TG production and increases in TG
clearance, coupled with efficient LDL particle clearance.
Such reductions in LDL particle number with IPE could
be related to the finding that IPE did not raise LDL-C in
either the MARINE or ANCHOR phase 3 clinical studies.
Ultimately, it remains to be determined if the potentially
beneficial effects of IPE on lipids, inflammation, and
lipoproteins translate into reduction in cardiovascular
events; the ANCHOR and MARINE studies were not
designed to assess the effect of IPE on cardiovascular
outcomes. However, the Japan EPA Lipid Intervention
Study found that treatment with purified EPA in addition
to statins reduced major coronary events in hypercholes-
terolemic patients.42,43 A large, ongoing, global, random-
ized, placebo-controlled phase 3 study (Reduction of
Cardiovascular Events with EPA–Intervention Trial
[REDUCE-IT; NCT01492361]) is evaluating the effect of
IPE 4 g/day in high-risk, statin-treated patients with hyper-
triglyceridemia for prevention of cardiovascular events.44Conclusions
Compared with placebo, treatment with IPE 4 g/day for
12 weeks in statin-treated patients with persistently high
TG levels ($200 and ,500 mg/dL) from the ANCHOR
study reduced key atherogenic lipoprotein particle concen-
trations and increased LDL particle size. At both baseline
and end of study, atherogenic lipoprotein concentrations
correlated with ApoB. These effects are consistent with the
TG-lowering activity of IPE, as demonstrated in the
ANCHOR study, and extend the efficacy findings to date
of IPE in statin-treated patients.Acknowledgments
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